Proxy Results (Form 8-K)

On Thursday, June 11, 2026, at 10:00 a.m. Eastern Time, by means of an online meeting platform, Nuvectis Pharma, Inc. (the "Company") held its 2026 Annual Meeting (the "Annual Meeting").

The Company's Definitive Proxy Statement on Schedule 14A (the "Proxy"), filed with the U.S. Securities and Exchange Commission (the "SEC") on April 27, 2026, inadvertently misstated the total number of shares of common stock outstanding as of the record date of April 13, 2026, as 27,668,036. The correct number of shares of common stock outstanding as of the record date was 26,614,628. This correction does not affect the validity of any votes cast at the Annual Meeting or the outcome of any proposal voted upon.

Stockholders representing 16,193,686, or 60.8%, of the 26,614,628 shares of common stock outstanding on the record date of April 13, 2026, were present in person or by proxy, constituting a quorum under applicable law. Proxies were solicited by the Company pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended. Each of the proposals below is described in detail in the Company's Proxy for the Annual Meeting, filed with the SEC on April 27, 2026. At the Annual Meeting, all of the proposals were approved.

The results are as follows:

Proposal 1

The vote with respect to the election of the Class I director to hold office until the 2029 annual meeting was as follows:

Proposal 2

The vote with respect to the ratification of Kesselman & Kesselman as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was as follows: